Filing Flows › Fennec Pharmaceuticals (FENC) › Q2 2026 › vs Q1 2026
Fennec Pharmaceuticals (FENC) Q2 2026 vs Q1 2026 (quarter over quarter)
Fennec Pharmaceuticals's revenue rose $2.8M (+18%) from $15.1M in Q1 2026 to $17.9M in Q2 2026. Operating margin 9.7% against -0.8% (+10.5 pts).
Fennec Pharmaceuticals, Q2 2026: revenue $17.9M (+85% year over year), operating margin 9.7%, net earnings $2.0M, operating cash flow $50K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 9.7% | -0.8% | +10.5 pts |
| Net margin | 11.0% | 1.3% | +9.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $2.8M | +18% |
| Other income, net | $278K | $320K | −$42K | -13% |
| Operating profit | $1.7M | −$119K | $1.9M | — |
| Costs & expenses | $16.1M | $15.2M | $910K | +6% |
| Pre-tax earnings | $2.0M | $201K | $1.8M | +902% |
| Research & development | $118K | $49K | $69K | +141% |
| Sales & marketing | $10.7M | $11.4M | −$763K | -7% |
| General & admin | $4.6M | $3.2M | $1.5M | +46% |
| Other operating costs | $721K | $570K | $151K | +26% |
| Net earnings | $2.0M | $201K | $1.8M | +882% |
| Income tax | $42K | $0 | $42K | — |
| Operating cash sources | $3.7M | $1.2M | $2.6M | +215% |
| Share-based compensation | $1.8M | $990K | $784K | +79% |
| Working capital & other | $3.7M | −$1.2M | $4.9M | — |
| Operating cash flow | $50K | $2.4M | −$2.3M | -98% |
Questions
How much did Fennec Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Fennec Pharmaceuticals's revenue rose $2.8M (+18%) from $15.1M in Q1 2026 to $17.9M in Q2 2026. Operating margin 9.7% against -0.8% (+10.5 pts).